Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Golden State Newswire.
Press releases published on June 1, 2025
Local Experts Share Top 5 Tips to Navigate the Mortgage Process for First-Time Homebuyers
EIN Presswire
·
June 1, 2025
ORANGE COUNTY, CA, UNITED STATES, June 1, 2025 /EINPresswire.com/ -- Buying a first home marks a significant life milestone, but the mortgage process can often feel overwhelming—particularly for those new to the real estate market. To provide clarity and …
Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML
GlobeNewswire
·
June 1, 2025
– New Drug Application based on positive results from the Phase 2 KOMET-001 trial – – FDA assigns a Prescription Drug User Fee Act (PDUFA) target action date of November 30, 2025 – – Potential first approval of a menin inhibitor for the treatment of adult …
DV INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that DoubleVerify Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit
GlobeNewswire
·
June 1, 2025
SAN DIEGO, June 01, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman …
RCAT INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Red Cat Holdings, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
GlobeNewswire
·
June 1, 2025
SAN DIEGO, June 01, 2025 (GLOBE NEWSWIRE) -- Robbins Geller Rudman …
Allogene Therapeutics Provides Updated Phase 1 Data Highlighting Durable Responses with ALLO-316 in Heavily Pretreated Advanced Renal Cell Carcinoma at ASCO
GlobeNewswire
·
June 1, 2025
Data Highlights Transformative Promise of CAR T in Solid Tumors Phase 1 Trial with ALLO-316 Demonstrated Potential to Provide Meaningful Clinical Benefit in Patients with CD70 TPS ≥ 50% Advanced or Metastatic RCC A Single Dose of ALLO-316 Achieved a 31% …
Seer’s Proteograph Platform Enables Unprecedented 20,000-Sample Proteomics Study with Korea University to Develop AI-Driven Diagnostics for Cancers in Young Adults
GlobeNewswire
·
June 1, 2025
First-of-its-kind study will use Seer’s next-generation workflow to identify early-onset cancer biomarkers and power deep, unbiased mass spectrometry-based proteomics Seer’s new Proteograph ONE Assay to accelerate analysis and reduce costs, making large- …